Cargando…

Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis

INTRODUCTION: The aim of this study was to compare the efficacy, safety and cost-utility (from the Chinese health insurance perspective) of lixisenatide and insulin regimens in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). METHODS: A compreh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Men, Peng, Qu, Shuli, Song, Zhenqiang, Liu, Yanjun, Li, Chaoyun, Zhai, Suodi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376816/ https://www.ncbi.nlm.nih.gov/pubmed/32562244 http://dx.doi.org/10.1007/s13300-020-00857-3

Ejemplares similares

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
por: Men, Peng, et al.
Publicado: (2018)

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis
por: Shu, Hua, et al.
Publicado: (2016)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men, Peng, et al.
Publicado: (2020)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
por: Hu, Xin, et al.
Publicado: (2019)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study
por: Temelkova, Nataliya, et al.
Publicado: (2019)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
por: Ahrén, Bo, et al.
Publicado: (2013)

PRISMA—efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Wei, Zhen-gang, et al.
Publicado: (2018)

Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis
por: Liu, Xin, et al.
Publicado: (2016)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis
por: Qiu, Tingting, et al.
Publicado: (2020)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis
por: Luo, Qiuhua, et al.
Publicado: (2019)

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
por: Rosenstock, Julio, et al.
Publicado: (2017)

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
por: Zhou, Pengxiang, et al.
Publicado: (2021)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response
por: Gu, Tianwei, et al.
Publicado: (2018)

Effects of inadequate coverage on healthcare utilization: A regression discontinuity analysis
por: Dugan, Jerome A., et al.
Publicado: (2021)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
por: Seino, Hiroaki, et al.
Publicado: (2016)

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
por: Ahrén, Bo, et al.
Publicado: (2016)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
por: Becker, Reinhard H. A., et al.
Publicado: (2015)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2020)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
por: Fournier, Marie, et al.
Publicado: (2014)

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate
por: Zimovetz, Evelina A., et al.
Publicado: (2016)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2011)

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
por: Wohlfart, Paulus, et al.
Publicado: (2013)

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
por: Hanefeld, Markolf, et al.
Publicado: (2017)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6f3tl73e6fnftbs2vst58srr9